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Abstract
Background: Eyes sustaining open globe trauma are at high risk of severe visual impairment. Ocular injuries which
result in visual loss invariably affect the posterior segment of the eye, and prevention of visual loss involves posterior
segment (vitreoretinal) surgery. Despite improvements in vitreoretinal surgical techniques, outcomes in these patients
remain unsatisfactory, and development of the intraocular scarring response proliferative vitreoretinopathy is the
leading cause. Proliferative vitreoretinopathy is the most common cause of recurrent retinal detachment in these eyes;
it is reported to occur in up to 45 % of cases.
(Continued on next page)
* Correspondence: rachel.phillips@kcl.ac.uk
4Department of Primary Care and Public Health Sciences, King’s College
London, London, UK
5National Institute for Health Research (NIHR) Biomedical Research Centre at
Guy’s and St. Thomas’ NHS Foundation Trust and King’s College London,
London, UK
Full list of author information is available at the end of the article
© 2016 Banerjee et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Banerjee et al. Trials  (2016) 17:339 
DOI 10.1186/s13063-016-1445-7
(Continued from previous page)
Methods/design: The Adjunctive Steroid Combination in Ocular Trauma (ASCOT) trial is a multi-centre, double-
masked, parallel-arm randomised controlled trial with an internal pilot designed to investigate the effectiveness and
cost-effectiveness of using intravitreal and sub-Tenon’s triamcinolone acetonide peri-operatively in patients undergoing
vitrectomy following open globe trauma. In total, 300 eyes of 300 patients will be recruited and randomly allocated
to one of two treatment groups. Both groups will receive standard surgical treatment and routine pre-operative and
post-operative treatment and care. The treatment group will receive an adjunctive peri-operative steroid combination
(triamcinolone acetonide) consisting of 4 mg/0.1 ml into the vitreous cavity and 40 mg/1 ml into the sub-Tenon’s
space. The trial incorporates a two-stage internal pilot to examine projected recruitment and retention rates.
Progression criteria from the internal pilot study will enable us to determine whether to undertake the main trial.
Patients and primary outcome assessors will be masked to treatment allocation. The primary outcome will be an
improvement from baseline to 6 months of at least 10 on the corrected visual acuity as measured by ETDRS letter
score. Secondary outcomes will be development of scarring, retinal detachment, intraocular pressure abnormalities,
quality of life and public sector service use.
Discussion: This is the first powered, controlled clinical trial to investigate the use of adjunctive triamcinolone in
patients undergoing vitrectomy following open globe trauma.
Trial registration: EudraCT2014-002193-37. Registered on 5 September 2014.
ISRCTN30012492. Registered on 5 September 2014.
Keywords: Open globe trauma, Proliferative vitreoretinopathy, Visual acuity, ETDRS, Ophthalmology, Randomised
controlled trial
Background
Trauma is an important cause of visual impairment and
blindness worldwide and a leading cause of blindness in
young adult males [1]. Globally, it has been estimated that
1.6 million people are blind as a result of ocular trauma,
with 2.3 million having bilateral low vision [2]. Ocular
trauma is the most common cause of unilateral blind-
ness in the world today, with up to 19 million individ-
uals having unilateral blindness or low vision [2]. It is
estimated that almost 1 million people in the United
States live with trauma-related visual impairment [3].
Ocular trauma has extensive socio-economic costs:
Patients with open globe injuries lose a mean of 70 days
of work [4]. In the United States, work-related eye
injuries costs over $300 million per year (http://
www.preventblindness.org/), which equates to an an-
nual cost to the U.K. economy (for which no compar-
able data exist) of £37.5 million.
In the United Kingdom, it is estimated that 5000 pa-
tients per year sustain eye injuries serious enough to
require hospital admission, and that 250 of these will
be permanently blind in the injured eye [5]. Recent
European studies document incidences of 2.4 and 3.2
per 100,000 per year [6, 7] for open globe injuries,
which suggests an annual incidence of between 1500
and 2000 for the United Kingdom.
Ocular injuries which result in visual loss frequently
affect the posterior segment of the eye, and prevention of
visual loss involves posterior segment (vitreoretinal) sur-
gery. It is clear on the basis of recent published data that,
although vitreoretinal surgical techniques have improved,
outcomes remain unsatisfactory, and development of the
intraocular scarring response proliferative vitreoretinopa-
thy (PVR) is the leading cause of this [8–11].
Proliferative vitreoretinopathy
Eyes sustaining penetrating or open globe trauma
(OGT) are at high risk of severe visual impairment. Ret-
inal detachment is common in these eyes, and multiple
surgical interventions are often necessary. PVR is the
most common cause of recurrent retinal detachment
and visual loss in eyes with OGT. It is documented to
occur in 10–45 % of all OGT cases [8–11], its incidence
varying with the nature of the penetrating injury [8].
PVR is a process of fibrocellular scar tissue formation,
which complicates 5–12 % of cases of primary retinal
detachment, 16–41 % of cases of giant retinal tears and
10–45 % of cases of posterior segment trauma [12]. PVR
represents a difficult vitreoretinal surgical challenge,
and, although final retinal attachment may now be
achieved, multiple surgeries are needed in many cases
and visual results are frequently poor [12, 13]. Binocular
vision outcomes are notably unsatisfactory in PVR [14].
PVR management is costly in terms of patient time and
healthcare resources [13].
Experimental data
Clinical observations and laboratory investigations
undertaken on eyes with PVR and surgical specimens
have identified potential targets for pharmacological
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adjuncts to surgical management of PVR [14]. The cellu-
lar components of PVR peri-retinal membranes (retinal
pigment epithelial, glial, inflammatory and fibroblastic
cells) proliferate and may also be contractile, and they
are thus targets for anti-proliferative agents. There is a
notable inflammatory component to the PVR process,
with marked blood-retinal barrier breakdown and a
greater tendency to intraocular fibrin formation [15].
Macrophages and T lymphocytes have been identified in
PVR membranes [14], and, although relatively small in
number, they may play an important role in membrane
development and contraction through growth factor
production. Thus, both cellular proliferation and the
intraocular inflammatory response are realistic targets
for adjunctive treatments in PVR.
Corticosteroid treatment can potentially influence
both the inflammatory and proliferative components of
PVR. Experimental work has suggested that the cortico-
steroid triamcinolone acetonide can reduce the severity
of PVR [16]. In addition, it has been demonstrated that
peri-ocular corticosteroids can reduce the severity of
experimental PVR [17]. Laboratory work has also demon-
strated that triamcinolone appears to have no significant
retinal toxicity [18], although in vitro it downregulates the
proliferation of retinal cells.
Clinical data
Clinically, intravitreal triamcinolone acetonide (IVTA)
has recently been extensively used to treat macular
oedema, intraocular inflammation and sub-retinal neo-
vascularisation without demonstrable retinal toxicity, but
with a notable incidence of raised intraocular pressure
(IOP) and cataracts. Previous small-scale, uncontrolled
clinical studies of PVR have suggested that systemic
prednisolone [19], infused dexamethasone [20] and
IVTA [21–23] may reduce the severity of PVR. An
external, single-centre pilot randomised controlled
trial (RCT) investigating intravitreal and sub-Tenon’s
triamcinolone as an adjunctive treatment in eyes
undergoing pars plana vitrectomy (PPV) following
OGT [24] suggested an improved visual outcome in
eyes receiving adjunctive corticosteroid treatment and
supported an adequately powered RCT to provide a
definitive answer [24].
Investigational medicinal product triamcinolone
acetonide
Triamcinolone is a hydrophobic, long-acting corticoster-
oid which is licensed for intra-articular use to treat arth-
ritis and for intramuscular use in a variety of systemic
inflammatory conditions. Ophthalmologists have experi-
ence using triamcinolone off-license via peri-ocular
administration for over 50 years, with administration via
the intraocular route adopted for over 30 years. It has
been used to treat a variety of posterior segment ocular
inflammatory pathologies [25–28]. Its use to visualise
the posterior hyaloid during PPV has been well estab-
lished [29]. Additionally, IVTA has been found to reduce
post-operative inflammation following vitrectomy sur-
gery [30]. It has been investigated specifically to deter-
mine its effect on vitreoretinal scarring, with varying
success [21–23]. It has an extremely well-documented
safety profile, with the most common side effect re-
corded as elevated IOP [31]. Data derived from a re-
cently published external pilot study [24] showed a
similar incidence of elevated IOP between both groups:
35 % (n = 7) of patients who received IVTA compared
with 25 % (n = 5) of those patients who received stand-
ard care.
Objectives
Internal pilot objectives
1. To ascertain recruitment rates and retention in
the first 6 months of the study being open to
recruitment
2. To verify the number of eligible participants across
centres
3. To assess the implementation of the trial and
adherence to the study protocol procedures in
non-teaching and teaching hospitals
4. To satisfy the criteria for proceeding to the main
trial
Primary objective
The aim of the main study is to determine whether ad-
junctive intraocular and peri-ocular steroid (triamcino-
lone acetonide) treatment improves visual acuity (VA) at
6 months compared with standard treatment in eyes
undergoing vitreoretinal surgery for OGT.
Secondary objectives
Secondary objectives of the study are to determine
whether adjunctive intraocular and peri-ocular steroid
(triamcinolone acetonide) treatment improves the devel-
opment of scarring (PVR), retinal detachment, IOP ab-
normalities and other complications in eyes undergoing
surgery for OGT. In addition, we will assess the effects
of treatment on quality of life as measured with the
EQ-5D and 25-item Visual Function Questionnaire
tools, as well as public sector service use to under-
take an economic evaluation using the Client Service
Receipt Inventory.
Methods/design
Study design
The Adjunctive Steroid Combination in Ocular Trauma
(ASCOT) study is a multi-centre, parallel-arm RCT in
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which patient and outcome assessor are masked. The
trial will test the superiority of the intervention at
6 months after vitrectomy surgery. A structured, in-
ternal, two-stage pilot with clear stop and go criteria is
included. In the pilot, we will examine projected recruit-
ment and retention rates. Pre-specified progression cri-
teria for each stage of the internal pilot will enable us to
decide whether to undertake the main trial, and data
from this two-stage internal pilot will contribute to the
final analysis.
Study population
Patients with an open globe injury undergoing vitrec-
tomy as either a primary or secondary procedure are the
study population being investigated. OGT is classified as
one of the following: (1) a full-thickness eyewall injury in
the form of a rupture caused by a blunt object or (2) a
laceration caused by a sharp object or an intraocular
foreign body. As the study intervention remains investi-
gational, in patients with bilateral eye injuries, the eye
with the worse injury (i.e., the eye with the poorest
visual potential according to the clinician’s discretion)
will be considered as the study eye for randomisation,
and the better eye will receive standard treatment. We
expect this to be a rare occurrence and are therefore not
stratifying by binocularity.
Patients will be eligible for inclusion if they meet the
following criteria:
1. Adult patients (aged 18 years or over at the time of
enrolment)
2. Full-thickness, OGT undergoing vitrectomy
3. Ability to give written informed consent
4. Willingness to accept randomisation and attend
follow-up for 6 months
Patients will be excluded if they meet the following
criteria:
1. Pre-existing uncontrolled uveitis
2. Definitive diagnosis of previous steroid-induced
glaucoma
3. Pregnant or breastfeeding females
4. Allergy or previous known adverse reaction to
triamcinolone acetonide
5. Current or planned systemic corticosteroid use
of a dose above physiological levels (e.g., >10 mg
prednisolone)
Informed consent
Informed consent will be obtained by a suitably qualified
and experienced individual who has been delegated this
duty by the chief investigator (CI) or the principal inves-
tigator (PI) (site-specific) on the delegation log. Rarely,
eligible patients may present for emergency surgery out
of hours or on occasions when the PI or a delegated
individual is not on-site. In such cases, informed con-
sent may be taken by individuals who are aware of
good clinical practice (GCP) and familiar with key as-
pects of the study.
Informed consent will be obtained before any trial-
specific procedures are completed (i.e., those that are
outside routine clinical care). Clinical findings docu-
mented during an ocular assessment that has been per-
formed as part of routine clinical care may be used to
populate the baseline Case Report Form (CRF), provided
the assessment is performed within 14 days before the
study intervention.
Randomisation
The randomisation procedure is performed intraopera-
tively at the time of the study vitrectomy, after final con-
firmation that the retina is attached. Randomisation is
conducted via a telephone service to the Emergency
Scientific and Medical Services (ESMS) global service
hosted at the King’s Clinical Trials Unit (KCTU) at
King’s College London. All randomised patients must
first be registered in the study electronic Case Re-
port Form (eCRF) system to be generated a unique
patient identification number (PIN). This will be
undertaken by the study team prior to the patient’s
going to the surgical theatre, but in some cases the
ESMS Global service may also assign a study PIN if
no member of the research team is available. Pa-
tients will be randomised in a 1:1 allocation ratio at
the level of the individual using random permuted
blocks, with stratification by trial site.
Interventions
Patients will be randomised to the treatment group or
the control group:
1. Treatment group: 4 mg/0.1 ml of IVTA will be
injected into the vitreous cavity following closure
of the scleral ports at the end of procedure, and
40 mg/1 ml of triamcinolone acetonide will be
given as a sub-Tenon’s injection at the end of the
procedure.
2. Control group: No additional adjunctive corticosteroid
medication will be administered, and standard care
will be given.
All patients will be advised to continue their routine
concomitant medications throughout the study, as there
is an extremely low likelihood of the investigational me-
dicinal product (IMP) reaching systemic concentrations
high enough to cause interactions.
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The following non-investigational medicinal products
(NIMPs) may be used by the patients in both groups in
their operated eye as part of their normal routine care:
1. Pre-operatively: Pupil-dilating drops may be instilled.
Local policy on pre-operative dilating agents will be
followed, but examples may include but are not re-
stricted to gutte cyclopentolate and gutte
phenylephrine.
2. Peri-operatively: Sub-conjunctival antibiotics will
be administered at the surgeon’s discretion in line
with the local pharmacy formulary (e.g., cefuroxime
[Zinacef; GlaxoSmithKline, Uxbridge, UK] 125 mg
or gentamicin in β-lactam-sensitive individuals).
Sub-conjunctival steroid injections may be adminis-
tered at the surgeon’s discretion (e.g., 4 mg dexa-
methasone or 4 mg betamethasone).
3. Post-operatively: Routine post-operative topical
antibiotics and cycloplegic drops may be used at
the discretion of the operating surgeon (e.g., gutte
chloramphenicol 0.5 % four times daily for 2 weeks,
gutte cyclopentolate 1.0 % three times daily for
1 week). Routine post-operative topical steroids may
be used at the surgeon’s discretion (e.g., gutte dexa-
methasone 0.1 % or gutte prednisolone acetate 1 %
with duration and frequency depending on the level
of post-operative inflammation).
The above NIMPs are detailed as a guide only. Local
policy for pre-, peri- and post-operative medications will
be followed and remain at the discretion of the operating
surgeon.
Outcomes
Internal pilot progression criteria
Stage 1: Funded study months 1–12 (recruitment
month 6) It is planned that five study sites will be set
up by month 4 and ten study sites by month 5. It is
anticipated that they should be recruiting participants to
the internal pilot at the start of month 6. The trial is to
proceed to stage 2 of the internal pilot if at funded study
month 12 the following are true:
1. Ten study sites are set up by month 10
and
2. At least 30 participants have been recruited to
the trial during the first 6 months of the
recruitment period
Stage 2: Funded study months 12–18 (recruitment
month 12) It is planned that 20 study sites will be set
up by study month 12 and are able to recruit partici-
pants at the start of month 13. The trial is to proceed
to full trial if at funded study month 18 the following
are true:
1. Less than 7 of 30 or less than 8 of 40 stage 1
internal pilot participants have withdrawn from
the trial by their 6-month follow-up appointment
and
2. An additional 48 participants have been recruited to
the trial during recruitment months 6–12
If the progression criteria for either stage 1 or stage 2
are not met due to an inadequate number of study sites
being open, the reasons for these delays will be exam-
ined and discussed with the funders. Reasons for failure
to meet recruitment and retention rate will be examined
in detail, and the feasibility of the trial will be assessed
in light of the information obtained from the internal
pilot. If appropriate, the recruitment targets will be re-
drawn, and further study sites will be added to the trial
in order to meet sample size requirements within the
funding period.
Main study outcomes
The primary outcome is the proportion of patients
with a clinically meaningful improvement of at least
10 on the corrected VA in the study eye measured
using validated Early Treatment Diabetic Retinopathy
Study (ETDRS) vision charts at a starting distance of
4 m from baseline to 6 months after initial surgery.
The following are secondary outcomes of the study:
1. Total ETDRS score in the study eye at the 6-month
follow-up appointment
2. The proportion of patients in whom retinal
detachment with PVR occurs at any time
point within 6 months of the study vitrectomy1
3. The proportion of patients in whom stable
complete retinal reattachment (without internal
tamponade present) is achieved at 6 months
post-study vitrectomy1
4. The proportion of patients in whom stable macular
retinal reattachment (without internal tamponade
present) is achieved at 6 months post-study
vitrectomy1
5. The proportion of patients in whom a tractional
retinal detachment occurs at any time point within
6 months of the study vitrectomy1
6. The number of operations to achieve stable
retinal reattachment (either complete or
macula) at 6 months after the study
vitrectomy1
7. The proportion of patients with hypotony
(<6 mmHg) at any time point within 6 months of
the study vitrectomy
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8. The proportion of patients with raised IOP
(>25 mmHg) at any time point within 6 months of
the study vitrectomy
9. The proportion of patients who develop macular
pucker by 3 and 6 months and/or require macular
pucker surgery at any time point within 6 months of
the study vitrectomy
Items 1–9 above apply to the study eye only.
10. Use of public sector resources:
(a)Client Service Receipt Inventory (CSRI): Primary
and secondary health and social care service use
will be recorded using a brief CSRI created for
the study. At baseline, patients will be asked to
recall service use in the last 4 weeks, and at 3 and
6 months patients will be asked to recall their
service use for the previous 3 months.
11. Quality of life (QoL) as measured with the following
instruments:
(a)EQ-5D-5L [32]: The EQ-5D is a generic,
preference-based, health-related quality of life
measure.
(b)Visual Function Questionnaire (VFQ-25) [33]:
The VFQ-25 measures vision-related QoL.
Sample size and recruitment
Published data [34] indicate that the distribution of the
best corrected VA ETDRS letter score at 6 months will
be skewed, which is in line with results from the external
pilot RCT [24]. In the external pilot trial, the majority of
patients (35 of 40) had a score of 0 for VA baseline
values, and the shape of the distribution of VA at
6 months was non-identical between the treatment
group and the control group. Both of these factors im-
pact the choice of suitable methods for analysis and thus
an appropriate approach to calculating the sample size.
As a result of a small mean difference and non-
identical distributions observed in VA between treat-
ment groups in the external pilot study, we chose to
define the primary outcome to be a clinically meaningful
improvement in VA of 10 letters or more in the treat-
ment group. A change of 10 letters is widely accepted to
be clinically meaningful in research studies of eye dis-
ease [13, 15, 19–22, 35–38].
With 140 patients per group and a significance value
of 5 %, we would have 90 % power to detect a 19 % in-
crease (from 55 % to 74 %) in patients who have a mean-
ingful minimum improvement in VA of at least 10. The
expected proportion in the control group is based on
the external pilot data, where we observed 55 % of pa-
tients gaining 10 ETDRS letters after vitrectomy surgery
for OGT [24]. Equivalently, with 140 per patients per
group and using a 5 % significance level, we would have
85 % power to detect a 17 % increase (from 55 % to 72 %)
in patients who have a meaningful minimum improve-
ment in VA of at least 10.
Previous trials run by Moorfields Eye Hospital and
involving tertiary teaching hospitals had no more than a
5 % dropout rate at 6-month follow-up [24, 35, 37, 38].
As our multi-centre trial includes non-specialist centres,
we anticipate the dropout rate will be higher. Therefore,
allowing for a 7 % dropout rate, we aim to recruit
300 patients to participate in the trial. All 300 pa-
tients will be identified and recruited from outpatient
clinics and emergency referrals at one of the specified
U.K. study sites.
Masking
Patients and primary outcome assessors will be masked
to treatment allocation. Outcome assessors may consist
of technicians, nursing staff or healthcare assistants who
are familiar with measuring VA using the ETDRS chart.
The operating surgeon is masked until the end of the
study operation at the point of randomisation.
Emergency unmasking
Within the first few days after IMP administration, there
is a possibility that the intraocular triamcinolone may
migrate into the anterior chamber. This may appear as a
pseudohypopyon, and the clinical picture could mimic
endophthalmitis. It is expected that patients will be
followed at their treatment site. Operating surgeons will
be encouraged to anticipate this occurrence and com-
municate this to the reviewing team in the immediate
post-operative period. However, it is possible (although
unlikely) that patients may attend a unit other than their
study site within the early post-operative period. In this
circumstance, a treating clinician should be made aware
of the patient’s treatment allocation if the patient
suspects a diagnosis of endophthalmitis, such that (1)
the patient is not subjected to unnecessary invasive
interventions where the findings are of an innocuous
pseudohypopyon or (2) urgent treatment is withheld
under the false premise that the observed hypopyon is a
pseudohypopyon.
The study code should be broken only for valid med-
ical or safety reasons highlighted in the circumstances
above where it is necessary for the investigator or treat-
ing healthcare professional to know which treatment the
patient is receiving before the patient can be treated as
per standard clinical care. Subject always to clinical
need, where possible, members of the study site research
team should remain masked. The procedures to be used
for unmasking during and out of office hours by study
physicians and other treating physicians follows a stand-
ard operating procedure (SOP) and the code breaks for
the trial are held by the ESMS global service.
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Data collection
Screening
Patients who are invited to attend the hospital specific-
ally for the purposes of screening will be asked to sign a
written consent form by a member of the study team or
a delegated individual. A full medical and ophthalmic
history will be obtained to confirm eligibility.
Baseline assessments
Baseline assessments will be performed within 14 days prior
to the study vitrectomy. Data collected as part of routine
clinical care may be used to populate the baseline CRF
prior to informed consent, but the patient will not be regis-
tered on the eCRF, and no data will be entered into the
eCRF system until the patient has signed a consent form.
The eCRF system will generate a unique study identifier for
all patients consented and screened for participation in the
study. The method of data collection will be a combination
of medical history, applanation tonometry, slit-lamp biomi-
croscopy or indirect ophthalmoscopy, and intraoperative
findings. QoL data will be collected using the ED-5Q and
VFQ-25 tools and a CSRI questionnaire. Screening and
baseline assessments may occur concurrently.
Subsequent assessments
Patient follow-up will mirror the schedule of standard
National Health Service (NHS) care with assessments at
3 months and 6 months post-surgery. Table 1 is a guide
for an expected schedule of visits. Data entry time points
will be at (1) baseline, (2) study vitrectomy, (3) month 3
and (4) month 6, with a 4-week time window allowed on
either side of the scheduled visit (refer to shaded
columns in schedule of visits in Table 1).
Table 1 Study assessments
The table may be used as a guide and represents routine standard care. Patients may require fewer visits (e.g., if silicone oil tamponade is not used, or more
frequent visits as their clinical need arises, such as reoperations). The restrictions on time windows allowed for scheduled visits relate only to data entry points
and are highlighted as shaded columns in the table (i.e., baseline, months 3 and 6)
Shaded columns = data collection points (i.e., eCRF completion required); black X = performed as part of routine NHS care; red X = performed in addition to
routine care as part of study
Abbreviations: ETDRS VA Early Treatment Diabetic Retinopathy Study visual acuity, IOP intraocular pressure, VFQ-25 25-itemVisual Functioning Questionnaire, EQ-5D
EuroQol health questionnaire, CSRI Client Service Receipt Inventory, CRF case report form, PPV pars plana vitrectomy, ROSO removal of silicone oil
aInvestigational medicinal product administration in treatment group
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Discontinuation/withdrawal of participants
Participants will be withdrawn from the study in the
following circumstances:
1. The administration of an intraocular or peri-ocular
corticosteroid is deemed necessary by the patient’s
consultant. (The use of intraocular triamcinolone as
a surgical adjunct to visualise the hyaloid is permit-
ted in both groups, as it is subsequently cleared in-
traoperatively. The likelihood of therapeutic doses
remaining at the end of the procedure is considered
to be extremely low.)
2. The patient is commenced on systemic
corticosteroids at a dose higher than physiological
levels (e.g., >10 mg oral prednisolone).
3. The patient expresses a wish to withdraw from
the trial.
Withdrawn subjects will not be replaced, as attrition
has been accounted for in the sample size calculation.
Participants who wish to withdraw will be asked if they
are willing to undertake VA assessment at 6 months and
supply other study data collected at this routine visit.
Data management
Study data will initially be recorded on a source data
worksheet and then transcribed to the eCRF system
(InferMed MACRO; Elsevier, London, UK) hosted at the
KCTU at King’s College London. It will be the responsi-
bility of the investigator to ensure the accuracy of all
data entered in the eCRFs. InferMed MACRO eCRF ver-
sion 4 will be used to record the study data.
All data will be handled in accordance with the U.K.
Data Protection Act 1998. The eCRFs will not bear the
patient’s name or other personally identifiable data. The
subject’s initials, date of birth and patient identification
number will be used for identification. Source data
worksheets will be completed for each patient but will
not be removed from the recruiting study sites. Signed
consent forms will be filed in the investigator site file.
A trial-specific monitoring plan will be established for
the study as part of the oversight planning. The trial will
be monitored with the agreed plan. The trial manager
will raise data discrepancies within the system, and sites
will respond to each before the discrepancy is closed. At
the end of the trial, once all queries are resolved and all
data fields are completed with data or missing data
codes (where applicable), the database will be locked for
analysis, and this process will be overseen by the KCTU.
Statistical methods
Summary of baseline data and flow of patients
A Consolidated Standards of Reporting Trials (CON-
SORT) flow diagram will be produced to show the
number of eligible patients, the number recruited and
randomised, and the number withdrawing with reasons
for withdrawal [39]. Baseline characteristics will be tabu-
lated and summarised by treatment arm. The primary
analysis will follow an intention-to-treat principle as spe-
cified in the International Conference on Harmonisation
(ICH) E9 guideline [40], whereby all participants are
analysed in the arm to which they were allocated, re-
gardless of subsequent procedures. The proportion of
patients with an improvement in VA score of 10 or more
in the study eye, as measured with the ETDRS vision
chart, will be compared between treatment groups.
Primary outcome analysis
The proportion of participants with improvement in VA
of 10 letters of more (yes or no) will be tabulated by
treatment arm and time point. Initially, we will calculate
an unadjusted difference in proportion at 6 months be-
tween treatment arms with 95 % confidence intervals.
We will obtain the adjusted treatment effect estimate by
fitting a generalised linear model with improvement in
VA of 10 letters of more (yes or no) as the outcome and
treatment group and baseline ETDRS value as covari-
ates. The treatment effect estimate will be reported with
a two-sided 95 % confidence interval and corresponding
p value. We will use a generalised linear model with bi-
nomial distribution and logit link function to calculate
the OR with associated 95 % confidence intervals. If
many centres recruit a small number of participants
(e.g., n < 5), a sensitivity analysis exploring suitable
methods to adjust for centre in the model will be under-
taken [41].
Secondary outcome analysis
We will undertake analysis of the secondary outcomes in
a similar manner to the primary analysis described
above. Secondary outcomes will be summarise and tabu-
lated by treatment arm and time point. We will estimate
and test for a difference between treatment arms for
each endpoint specified in the secondary outcomes listed
above. Initially, we will calculate an unadjusted differ-
ence and 95 % confidence interval. A suitable general-
ised linear model will then be fitted for each outcome
The logit link and binomial distribution will be used for
binary outcomes, the identity link and Gaussian distribu-
tion will be used for continuous outcomes, and the log
link and Poisson distribution will be used for count out-
comes, which will include an overdispersion parameter if
required. Similarly to the primary outcome analysis, the
models will include treatment group, baseline ETDRS
value and centre as covariates where appropriate. We
will assess all outcomes at the 6-month time point.
Adverse events (AE), adverse reactions (AR), serious
adverse events (SAE) and serious adverse reactions
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(SAR) will be summarised. AE will be tabulated by treat-
ment arm for both the number of events and the num-
ber of participants with events. No formal comparisons
will be made.
All statistical tests and confidence intervals will be
two-sided. Statistical significance will be considered at
the 5 % level, and confidence intervals will be at the
95 % level [42].
Health economics analysis
We will analyse the incremental cost-effectiveness of the
trial intervention (intraocular and peri-ocular steroid) in
eyes undergoing vitreoretinal surgery for ocular trauma
compared with surgery alone in terms of changes in VA.
To enable this analysis, we will, from a public sector,
multi-agency perspective [42–44]:
1. Fully cost the vitreoretinal surgery and follow-up
2. Record patients’ primary and secondary care health
service use and social care use over the 6-month
follow-up (using a research nurse interviewer-
administered CSRI, costed using national unit costs
[45, 46], and making use of routine hospital data on
surgical and post-operative care as part of the CRF)
3. Conduct a primary cost-effectiveness analysis (using
the trial primary outcome measure of VA as our
measure of effectiveness)
4. Conduct a secondary cost-consequence analysis (to
take account of impact on wider effects such as em-
ployment and VA), including calculation of quality-
adjusted life-years (QALYs) using the EQ-5D ques-
tionnaire as our measure of utility to generate a cost
per QALY for comparison with the National Insti-
tute for Health and Care Excellence ceiling of
£20,000–£30,000 [47]
5. Through bootstrapping, generate cost-effectiveness
acceptability curves to communicate to policy
makers the probability that the intervention is cost-
effective [48]
6. Undertake sensitivity analysis to explore uncertainty
by varying key assumptions in our analysis
A detailed statistical/health economics analysis plan
has been developed and approved by the Trial Steering
Committee (TSC). Masked statisticians will be respon-
sible for overseeing all the statistical aspects of the trial,
and a sub-group unmasked statistician will be respon-
sible for undertaking interim analysis for Data Monitor-
ing and Ethics Committee (DMEC) reports and final
study analysis.
Data monitoring
The overall management structure of this study will con-
sist of the Trial Management Group (TMG), the TSC
and a DMEC. The TMG will be responsible for the day-
to-day running and management of the trial. The TSC
will ensure the overall integrity of the study by monitor-
ing its progress and taking account of regular reports
from the DMEC and TMG. The TSC will consist of an
independent chair and other members including an in-
dependent retinal specialist, a trauma specialist and a
patient and public involvement representative. The TSC
is expected to meet annually (or more often, if deter-
mined by the chair). The DMEC will independently
monitor the trial data to ensure that the trial is being
implemented in accordance with the highest standards
of patient safety and ethical conduct according to a pre-
planned charter based on the DAMOCLES Study Group
report [49, 50]. Throughout the trial, the DMEC will
monitor data on recruitment, AE, emerging external evi-
dence, sample characteristics and primary outcome, and
will make recommendations.
Adverse events and safety reporting
Safety reporting will adhere to the sponsor’s SOPs, and
monitoring, recording and reporting of AE will be car-
ried out in line with the Medicines and Healthcare prod-
ucts Regulatory Agency (MHRA) guidelines. AE will be
recorded with clinical symptoms and accompanied with
a simple, brief description of the event, including dates
as appropriate. AE will be reportable to the sponsor for
each patient for the duration of the patient’s participa-
tion in the trial as per the protocol.
Ocular AE
All ocular AE reported by patients and observed by the
study team will be recorded in the medical records and
the eCRF following randomisation until the patient has
completed the final study visit at 6 months, with the ex-
ception of some events which are inevitable conse-
quences of the surgical intervention and extremely
unlikely to be IMP-related. These events will only be re-
corded in the medical records and will be discussed fur-
ther herein.
The following expected ocular events will be considered
AE and will be actively monitored for by the investigators:
elevated IOP, hypotony (IOP <6 mmHg), pseudohypop-
yon, retinal detachment, further ocular surgery, endoph-
thalmitis, scleritis, uveitis and rubeosis. AE will be
recorded regardless of whether they are considered to be
drug-related or expected or unexpected. The recording of
severity of raised IOP will be done as follows:
1. Mild: >25 mmHg but <35 mmHg
2. Moderate: ≥35 mmHg
3. Severe: Any interventional invasive procedure
(e.g., surgery/laser) required to control the elevated
IOP acutely or long-term during the study period
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Examples of ocular events that will not be considered
AE on the basis of being expected findings in this dis-
ease population, and which as such will only be recorded
in the medical notes, include sub-conjunctival haemor-
rhage, conjunctival chemosis, peri-orbital oedema, routine
post-operative pain, cataract, and corneal epithelial defect
secondary to intraoperative epithelial debridement. If any
of the above events occur with a severity or duration that
is unexpected by the PI, they may then be reported as AE
with clear reasons given (e.g., ‘prolonged post-operative
pain’ or ‘severe sub-conjunctival haemorrhage’). All ocular
events that meet the definition of SAE will be recorded in
the medical notes, the eCRF and the SAE log.
Non-ocular AE
As the IMP is administered locally and the systemic ab-
sorption negligible, the likelihood of a non-ocular event
being related to IMP administration is extremely low
[36]. As this trial is an effectiveness trial, detailed AE
reporting on non-ocular events is not required to answer
the research question. Therefore, if a non-ocular AE oc-
curs, it will be recorded in the medical notes and logged
on the eCRF only if it may be considered an AR (i.e.,
possibly, probably or definitely IMP-related). All non-
ocular events that meet the definition of SAE will be re-
corded in the medical notes but will be recorded in the
eCRF and SAE log only if they are possibly, probably or
definitely IMP-related (i.e., a SAR).
All SAEs are immediately reportable to the sponsor
(within 24 h of the investigator becoming aware of it). All
suspected unexpected serious adverse reactions (SUSARs)
will be processed by the sponsor, which will notify the re-
search ethics committee (REC) and MHRA within 7 cal-
endar days if fatal or life-threatening or 15 calendar days
otherwise. The sponsor will prepare a report on the
SUSAR with the CI and submit the completed report to
the SUSAR system. The sponsor, together with the CI and
trial manager, will inform the PIs, DMEC and REC with a
copy of the report. The assessment of relationship of AEs
to the administration of IMP is a clinical decision made by
the investigators on the basis of all available information
at the time of the completion of the case report form.
The study will be conducted in accordance with the
ICH GCP guideline [51], as set out in the European Union
Clinical Trials Directive [52] and associated U.K. regula-
tions [53] and all subsequent amendments. The study will
comply at all times with the Declaration of Helsinki [54].
This protocol is reported in accordance with the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT 2013) checklist (see Additional file 1) [55].
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Discussion
This aim of this multi-centre RCT investigating the use
of a triamcinolone acetonide is to test the hypothesis
that adjunctive triamcinolone acetonide, given at the
time of surgery, can improve the outcome of vitreoret-
inal surgery for OGT. We will specifically analyse the
influence of the study intervention on VA, the incidence
of retinal detachment and the development of scarring
(proliferative vitreoretinopathy) in patients with OGT.
Side effects and complications will be monitored and
reported. We will undertake QoL assessments of the
study patients, and a cost-effectiveness analysis will
be carried out.
We have based the projected recruitment on data de-
rived from the external pilot study at the principal study
site, in addition to projections provided by participating
sites following local internal audits. Due to the poor
prognosis associated with current standard treatment,
we expect a high recruitment uptake following success-
ful eligibility screening as observed in the external pilot.
However, we have designed the study with a two-stage
internal pilot to assess recruitment and retention. Pro-
gression criteria for each stage of the internal pilot will
determine the decision whether to undertake the main
trial, and data from this two-stage internal pilot will con-
tribute to the final analysis.
We accept that, as our eligibility criteria are inclusive
and relatively unrestricted, it is likely that the cohort will
be a heterogeneous group. The severity of open globe in-
jury may range from a relatively minor injury at one end
of the spectrum (i.e., a small anterior corneal wound and
secondary lens capsule breach requiring a posterior
vitreolensectomy) to a severe posterior globe rupture
with total retinal detachment and extensive suprachoroi-
dal haemorrhage. However, we expect the adequacy of
randomisation to compensate for this and shall acknow-
ledge any unequal weighting within the groups as limita-
tions of the study. However, we accept that we may limit
our sensitivity analysis to small differences between the
two groups.
The authors have designed the study to reduce investi-
gator bias by masking the primary outcome assessors,
the patients and the operating surgeons (until the point
of randomisation). The investigators are not formally
masked to the treatment allocations, as the IMP is
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sometimes visible on posterior chamber assessment for
up to 4 weeks. However, data entry points for secondary
outcomes are at 3 and 6 months post-injection, and thus
knowledge of individual patients’ treatment allocation at
these time points is unlikely.
In summary, this is the first powered RCT to investi-
gate the use of triamcinolone in patients undergoing vi-
trectomy surgery following OGT, with an accompanying
economic evaluation.
Trial status
The authors confirm that the trial remained in active
recruitment as of the 14th July 2016.
Endnotes
1Assessed by clinician examining the patient as part of
usual clinical visits.
Additional file
Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 114 kb)
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